Literature DB >> 22129593

Dosing of piperacillin/tazobactam in a morbidly obese patient.

Hanna Deman, Jan Verhaegen, Ludo Willems, Isabel Spriet.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22129593     DOI: 10.1093/jac/dkr503

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  6 in total

1.  The Daniel K. Inouye College of Pharmacy Scripts: Obesity: The Drug Dose Debate.

Authors:  Cherie Chu; Louis Lteif; Nicole Young
Journal:  Hawaii J Med Public Health       Date:  2017-06

2.  Information provision for antibacterial dosing in the obese patient: a sizeable absence?

Authors:  Sara Elizabeth Boyd; Esmita Charani; Tracy Lyons; Gary Frost; Alison Helen Holmes
Journal:  J Antimicrob Chemother       Date:  2016-08-18       Impact factor: 5.790

3.  Obesity Is Not Associated with Antimicrobial Treatment Failure for Intra-Abdominal Infection.

Authors:  Zachary C Dietch; Therese M Duane; Charles H Cook; Patrick J O'Neill; Reza Askari; Lena M Napolitano; Nicholas Namias; Christopher M Watson; Daniel L Dent; Brandy L Edwards; Puja M Shah; Christopher A Guidry; Stephen W Davies; Rhett N Willis; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2016-03-30       Impact factor: 2.150

4.  Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin-Tazobactam in Obese Patients.

Authors:  John J Veillette; S Alexander Winans; Victoria K Maskiewicz; James Truong; Ronald N Jones; Steven C Forland
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-03-20       Impact factor: 2.569

Review 5.  Antibiotic therapy of pneumonia in the obese patient: dosing and delivery.

Authors:  Hasan M Al-Dorzi; Shmylan A Al Harbi; Yaseen M Arabi
Journal:  Curr Opin Infect Dis       Date:  2014-04       Impact factor: 4.915

6.  Broad-spectrum β-lactams in obese non-critically ill patients.

Authors:  M Hites; F S Taccone; F Wolff; E Maillart; M Beumier; R Surin; F Cotton; F Jacobs
Journal:  Nutr Diabetes       Date:  2014-06-23       Impact factor: 5.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.